Induction of ERBB2 nuclear transport after radiation in breast cancer cells

被引:0
|
作者
Bo Luo
Shiying Yu
Liang Zhuang
Shu Xia
Zhen Zhao
Lei Rong
机构
[1] Huazhong University of Science and Technology,Department of Oncology, Tongji Hospital, Tongji Medical College
关键词
c-ERBB-2; breast cancer; radiosensitivity;
D O I
暂无
中图分类号
学科分类号
摘要
The ERBB2 nuclear transport in breast cancer cell lines after radiation and its possible role in radiation tolerance were observed. Confocal microscopy and Western blotting were applied to detect the nuclear ERBB2 expression after radiation in breast carcinomas cells. And the effects of Herceptin, AG825 and Cisplatin on the expression of nuclear ERBB2 were investigated. Survival fractions were also observed. After radiation, compared with control group, confocal microscopy and Western blot revealed that the expression of nuclear ERBB2 was increased in breast cancer cells time-dependently. Herceptin, and AG825 could significantly inhibit the radiation-induced nuclear ERBB2 expression, and decrease survival fractions. Cisplatin also induced the nuclear ERBB2 expression in breast cancer cells with high ERBB2 expression. It was concluded that radiation could induce ERBB2 nuclear transport, and nuclear ERBB2 may correlate with radiation resistance in breast cancer cells with high ERBB2 expression.
引用
收藏
页码:350 / 353
页数:3
相关论文
共 50 条
  • [31] MiR-34a modulates ErbB2 in breast cancer
    Wang, Yilin
    Zhang, Xiaolong
    Chao, Zou
    Kung, Hsiang-Fu
    Lin, Marie C.
    Dress, Andreas
    Wardle, Fiona
    Jiang, Bing-Hua
    Lai, Lihui
    CELL BIOLOGY INTERNATIONAL, 2017, 41 (01) : 93 - 101
  • [32] The ErbB2 signaling network as a target for breast cancer therapy
    Badache, Ali
    Goncalves, Anthony
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2006, 11 (01) : 13 - 25
  • [33] The potential role of the EGFR/ERBB2 heterodimer in breast cancer
    Cicenas, Jonas
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (06) : 607 - 616
  • [34] The ErbB2 Signaling Network as a Target for Breast Cancer Therapy
    Ali Badache
    Anthony Gonçalves
    Journal of Mammary Gland Biology and Neoplasia, 2006, 11 : 13 - 25
  • [35] Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores
    Robbins, Charles J. J.
    Fernandez, Aileen I. I.
    Rimm, David L. L.
    JAMA ONCOLOGY, 2023, 9 (09) : 1298 - 1299
  • [36] MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance
    Paulson, Amanda K.
    Linklater, Erik S.
    Berghuis, Bree D.
    App, Colleen A.
    Oostendorp, Leon D.
    Paulson, Jayne E.
    Pettinga, Jane E.
    Melnik, Marianne K.
    Woude, George F. Vande
    Graveel, Carrie R.
    MOLECULAR CANCER RESEARCH, 2013, 11 (09) : 1112 - 1121
  • [37] Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
    Eya Wolfson
    Shira Solomon
    Eran Schmukler
    Yona Goldshmit
    Ronit Pinkas-Kramarski
    Cell Death & Disease, 9
  • [38] Aberrations of ERBB2 and TOP2A genes in breast cancer
    Nielsen, Kirsten Vang
    Muller, Sven
    Moller, Susanne
    Schonau, Andreas
    Balslev, Eva
    Knoop, Ann S.
    Ejlertsen, Bent
    MOLECULAR ONCOLOGY, 2010, 4 (02) : 161 - 168
  • [39] Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
    Wolfson, Eya
    Solomon, Shira
    Schmukler, Eran
    Goldshmit, Yona
    Pinkas-Kramarski, Ronit
    CELL DEATH & DISEASE, 2018, 9
  • [40] Clinical and genomic landscape of ERBB2 and ERBB3 mutated breast cancer
    Bilani, Nadeem
    Tao, Jacqueline
    Safonov, Anton
    Casey, Dana
    Drago, Joshua
    Ahmed, Mehnaj
    Acevedo, Barbara
    Jhaveri, Komal
    Reis-Filho, Jorge
    Robson, Mark
    Toska, Eneda
    Hanker, Ariella
    Arteaga, Carlos
    Chandarlapaty, Sarat
    Wen, Hanna Y.
    Razavi, Pedram
    CANCER RESEARCH, 2024, 84 (09)